Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Week in Review: Mulititude Out-Licenses Tissue Factor ADC to Adcendo in $1 Billion Deal

publication date: Aug 24, 2024
 | 
author/source: Richard Daverman, PhD

Deals and Financings

Shanghai Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor (TF) ADC to Denmark’s Adcendo in a $1 billion agreement (see story). The candidate, ADCE-T02, is a highly differentiated anti-TF ADC with a Topoisomerase I inhibitor-based linker/payload, according to Multitude. The $1 billion value of the agreement includes upfront and milestone payments, with potential royalties on sales also available. Multitude is starting a Phase I trial of the candidate in Australia, with additional trials planned for the US and EU. 

Hangzhou’s Huadong Pharmaceutical acquired rights for two immune disease therapies from IMBiologics of South Korea in a $383 million agreement plus royalties (see story). $8 million of the total are upfront payments. The two candidates are both antibodies: IMB-101 is a bispecific that targets both the autoimmune disease antibody OX40L and tumor necrosis factor (TNF); IMB-102 is a monospecific antibody IMB-102 that targets OX40L. Earlier this year, IMBiologics sold US rights to the pair in a $995 million deal with Navigator Medicines. 

Finland’s Bone Index, a company that develops bone health diagnostic devices, completed a funding round with Lynx Financial (HK) Limited (see story). Bone Index has developed a product that offers a quick, accurate measurement of bone health, in early screening and hospital settings. The company's product has been approved for use in the US and EU. Lynx is an investment firm that provides a bridge to Asia for Life Sciences and Medical Technology companies. 

India’s Dr. Reddy’s Laboratories, together with its CRDMO Aurigene Pharmaceutical, signed a non-binding MOU with Kainomyx, a US company, to develop an affordable anti-malaria drug (see story). Kainomyx discovers small molecule therapeutics for neglected tropical diseases, with a focus on malaria. It targets cytoskeletal proteins of parasites to advance drug development and offers tests to identify asymptomatic carriers. According to the companies, the MOU combines Kainomyx’s novel drug discovery expertise, Aurigene’s experience with integrated drug discovery and development, and Dr. Reddy’s commercialization ability, especially in low and middle-income countries. 

EA Pharma sold global rights for a small molecule calcimimetic that may control intact parathyroid hormone levels in patients with secondary hyperparathyroidism receiving hemodialysis (see story). Upacicalcet is an intravenous therapy. EA Pharma, a subsidiary of Eisai Pharma of Japan, sold the rights to North Carolina’s Pathalys Pharma, a biopharma that develops best-in-class therapies for chronic kidney diseases. At the same time, Pathalys received an initial seed financing from DaVita Venture Group, and Catalys Pacific. Catalys Pacific is a Tokyo-San Francisco investor. 

Merck (MSD) has altered its mammoth ADC partnership with Sichuan’s Kelun-Biotech by adding one candidate and dropping another (see story). In 2022, Merck made major news by entering three partnerships with Kelun worth a maximum of $12.7 billion. Now, Merck plans to acquire a global license to SKB571, a bispecific ADC aimed at solid tumor cancers, paying $37.5 million upfront. At the same time, it returned rights to SKB315, a CLDN18.2 ADC. The agreement between the two companies is well underway: Kelun received $90 million in milestone payments from Merck in the first half of 2024. 

Trials and Approvals

GenFleet Therapeutics was approved for a China launch KRAS G12C inhibitor, as a second-line treatment for advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation (see story). Patients must have previously had at least one systemic therapy. About 85% of all lung cancers are NSCLC, and KRAS is the most frequently mutated driver gene in NSCLC. The approve is a first in China for a KRAS G12C inhibitor. In 2021, GenFleet out-licensed greater China commercialization rights for fulzerasib to Suzhou’s Innovent in a deal worth up to $315 million. 

Disclosure: none.


 

Share this with colleagues:

 

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here